{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:37:28Z","timestamp":1785544648969,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja (Slovak Research and Development Agency)","doi-asserted-by":"publisher","award":["APVV-0052-12"],"award-info":[{"award-number":["APVV-0052-12"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja (Slovak Research and Development Agency)","doi-asserted-by":"publisher","award":["APVV-0583-11"],"award-info":[{"award-number":["APVV-0583-11"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV (Scientific Grant Agency)","doi-asserted-by":"publisher","award":["VEGA 02\/0178\/17"],"award-info":[{"award-number":["VEGA 02\/0178\/17"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41417-018-0030-5","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:41:36Z","timestamp":1529322096000},"page":"285-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme\/prodrug treatment"],"prefix":"10.1038","volume":"25","author":[{"given":"Erika","family":"Durinikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Plava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tyciakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Skvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vojs Stanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Kozovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Kucerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Matuskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"30_CR1","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/0008-5472.CAN-06-4024","volume":"67","author":"L Kucerova","year":"2007","unstructured":"Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304\u201313.","journal-title":"Cancer Res"},{"key":"30_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/mt.2010.58","volume":"18","author":"D Bexell","year":"2010","unstructured":"Bexell D, Scheding S, Bengzon J. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther. 2010;18:1067\u201375.","journal-title":"Mol Ther"},{"key":"30_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/0929867323666151217122033","volume":"23","author":"H Mirzaei","year":"2016","unstructured":"Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H, et al. Application of mesenchymal stem cells in melanoma: a potential therapeutic strategy for delivery of targeted agents. Curr Med Chem. 2016;23:455\u201363.","journal-title":"Curr Med Chem"},{"key":"30_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/mt.2009.237","volume":"18","author":"IT Cavarretta","year":"2010","unstructured":"Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther. 2010;18:223\u201331.","journal-title":"Mol Ther"},{"key":"30_CR5","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/ijc.28455","volume":"134","author":"C Altaner","year":"2014","unstructured":"Altaner C, Altanerova V, Cihova M, Ondicova K, Rychly B, Baciak L, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer. 2014;134:1458\u201365.","journal-title":"Int J Cancer"},{"key":"30_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4149\/av_2014_01_3","volume":"58","author":"E Durinikova","year":"2014","unstructured":"Durinikova E, Kucerova L, Matuskova M. Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy. Acta Virol. 2014;58:1\u201313.","journal-title":"Acta Virol"},{"key":"30_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mam.2006.12.001","volume":"28","author":"D Portsmouth","year":"2007","unstructured":"Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Asp Med. 2007;28:4\u201341.","journal-title":"Mol Asp Med"},{"key":"30_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/gt.2014.66","volume":"21","author":"L Kucerova","year":"2014","unstructured":"Kucerova L, Skolekova S, Demkova L, Bohovic R, Matuskova M. Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC\/5FC therapy in human melanoma xenograft model. Gene Ther. 2014;21:874\u201387.","journal-title":"Gene Ther"},{"key":"30_CR9","first-page":"342","volume":"44","author":"J Hlavaty","year":"1997","unstructured":"Hlavaty J, Hlubinova K, Altanerova V, Liska J, Altaner C. Treatment of rat gliomas with recombinant retrovirus harboring Herpes simplex virus thymidine kinase suicide gene. Neoplasma. 1997;44:342\u20137.","journal-title":"Neoplasma"},{"key":"30_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-129","volume":"9","author":"L Kucerova","year":"2010","unstructured":"Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129.","journal-title":"Mol Cancer"},{"key":"30_CR11","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/0008-5472.CAN-06-4024","volume":"67","author":"L Kucerova","year":"2007","unstructured":"Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304\u201313.","journal-title":"Cancer Res"},{"key":"30_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jgm.1239","volume":"10","author":"L Kucerova","year":"2008","unstructured":"Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med. 2008;10:1071\u201382.","journal-title":"J Gene Med"},{"key":"30_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2011.07.014","volume":"311","author":"L Kucerova","year":"2011","unstructured":"Kucerova L, Matuskova M, Hlubinova K, Bohovic R, Feketeova L, Janega P, et al. Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine. Cancer Lett. 2011;311:101\u201312.","journal-title":"Cancer Lett"},{"key":"30_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/ijc.26278","volume":"130","author":"V Altanerova","year":"2012","unstructured":"Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, Mravec B, et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosine deaminase::uracil phosphoribosyl transferase inhibit intracerebral rat glioblastoma. Int J Cancer. 2012;130:2455\u201363.","journal-title":"Int J Cancer"},{"key":"30_CR15","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1016\/j.ejca.2014.06.014","volume":"50","author":"A Abrate","year":"2014","unstructured":"Abrate A, Buono R, Canu T, Esposito A, Del Maschio A, Luciano R, et al. Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. Eur J Cancer. 2014;50:2478\u201388.","journal-title":"Eur J Cancer"},{"issue":"21","key":"30_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1089\/scd.2016.0064","volume":"25","author":"Lenka Toro","year":"2016","unstructured":"Toro L, Bohovic R, Matuskova M, Smolkova B, Kucerova L. Metastatic ovarian cancer can be efficiently treated by genetically modified mesenchymal stromal cells. Stem Cells Dev. 2016;25:1640-51.","journal-title":"Stem Cells and Development"},{"key":"30_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/jgm.2684","volume":"14","author":"M Matuskova","year":"2012","unstructured":"Matuskova M, Baranovicova L, Kozovska Z, Durinikova E, Pastorakova A, Hunakova L, et al. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J Gene Med. 2012;14:776\u201387.","journal-title":"J Gene Med"},{"key":"30_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.08.016","volume":"408","author":"L Kucerova","year":"2017","unstructured":"Kucerova L, Durinikova E, Toro L, Cihova M, Miklikova S, Poturnajova M, et al. Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells. Cancer Lett. 2017;408:1\u20139.","journal-title":"Cancer Lett"},{"key":"30_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13046-015-0149-2","volume":"34","author":"M Matuskova","year":"2015","unstructured":"Matuskova M, Kozovska Z, Toro L, Durinikova E, Tyciakova S, Cierna Z, et al. Combined enzyme\/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases. J Exp Clin Cancer Res. 2015;34:33.","journal-title":"J Exp Clin Cancer Res"},{"key":"30_CR20","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","volume":"69","author":"NA Dallas","year":"2009","unstructured":"Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69:1951\u20137.","journal-title":"Cancer Res"},{"key":"30_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2009.08.028","volume":"290","author":"M Matuskova","year":"2010","unstructured":"Matuskova M, Hlubinova K, Pastorakova A, Hunakova L, Altanerova V, Altaner C, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010;290:58\u201367.","journal-title":"Cancer Lett"},{"key":"30_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4149\/neo_2015_063","volume":"62","author":"R Bohovic","year":"2015","unstructured":"Bohovic R, Demkova L, Cihova M, Skolekova S, Durinikova E, Toro L, et al. 3D multicellular models reflect the efficiency of MSC-directed enzyme\/prodrug treatment. Neoplasma. 2015;62:521\u201330.","journal-title":"Neoplasma"},{"key":"30_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jconrel.2015.01.003","volume":"200","author":"FS Nouri","year":"2015","unstructured":"Nouri FS, Wang X, Hatefi A. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme\/prodrug systems. J Control Release. 2015;200:179\u201387.","journal-title":"J Control Release"},{"key":"30_CR24","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.3748\/wjg.v11.i44.6910","volume":"11","author":"F Graepler","year":"2005","unstructured":"Graepler F, Lemken ML, Wybranietz WA, Schmidt U, Smirnow I, Gross CD, et al. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol. 2005;11:6910\u20139.","journal-title":"World J Gastroenterol"},{"key":"30_CR25","first-page":"2686","volume":"5","author":"JH Jung","year":"2015","unstructured":"Jung JH, Kim AA, Chang DY, Park YR, Suh-Kim H, Kim SS. Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells. Am J Cancer Res. 2015;5:2686\u201396.","journal-title":"Am J Cancer Res"},{"key":"30_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.7150\/thno.14158","volume":"6","author":"T Chung","year":"2016","unstructured":"Chung T, Na J, Kim YI, Chang DY, Kim H, Moon HE, et al. Dihydropyrimidine dehydrogenase is a prognostic marker for mesenchymal stem cell-mediated cytosine deaminase gene and 5-fluorocytosine prodrug therapy for the treatment of recurrent gliomas. Theranostics. 2016;6:1477\u201390.","journal-title":"Theranostics"},{"key":"30_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pgs.10.167","volume":"12","author":"M Scartozzi","year":"2011","unstructured":"Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, et al. 5-fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251\u201365.","journal-title":"Pharmacogenomics"},{"key":"30_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/0006-2952(95)00067-A","volume":"49","author":"S Copur","year":"1995","unstructured":"Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 1995;49:1419\u201326.","journal-title":"Biochem Pharmacol"},{"key":"30_CR29","first-page":"1407","volume":"55","author":"PG Johnston","year":"1995","unstructured":"Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55:1407\u201312.","journal-title":"Cancer Res"},{"key":"30_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/annonc\/mdf054","volume":"13","author":"E Cutsem Van","year":"2002","unstructured":"Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B. Raltitrexed: current clinical status and future directions. Ann Oncol. 2002;13:513\u201322.","journal-title":"Ann Oncol"},{"key":"30_CR31","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3892\/ol.2017.6512","volume":"14","author":"R Mori","year":"2017","unstructured":"Mori R, Futamura M, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K, et al. 5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine. Oncol Lett. 2017;14:3162\u20138.","journal-title":"Oncol Lett"},{"key":"30_CR32","first-page":"1322","volume":"6","author":"D Salonga","year":"2000","unstructured":"Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322\u20137.","journal-title":"Clin Cancer Res"},{"key":"30_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1241-x","volume":"15","author":"H Niess","year":"2015","unstructured":"Niess H, von Einem JC, Thomas MN, Michl M, Angele MK, Huss R, et al. Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I\/II clinical trial. BMC Cancer. 2015;15:237.","journal-title":"BMC Cancer"},{"key":"30_CR34","doi-asserted-by":"crossref","first-page":"80156","DOI":"10.18632\/oncotarget.20964","volume":"8","author":"JC Einem von","year":"2017","unstructured":"von Einem JC, Peter S, Gunther C, Volk HD, Grutz G, Salat C, et al. Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial. Oncotarget. 2017;8:80156\u201366.","journal-title":"Oncotarget"},{"key":"30_CR35","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1128\/AAC.01103-09","volume":"54","author":"MP Pai","year":"2010","unstructured":"Pai MP, Bruce H, Felton LA. Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother. 2010;54:1237\u201341.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0030-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:53Z","timestamp":1684616993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":35,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0030-5","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"31 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}